Smoking and tobacco use are major risk factors for many diseases including lung and head and neck (H&N) cancer. A long term goal is to establish susceptibility markers for lung and H&N cancer to identify tobacco users at higher risk for these cancers. UDP-glycosyltransferase (UGT) enzymes play a critical role in the detoxification of many carcinogens abundant in tobacco and/or tobacco smoke including polycyclic aromatic hydrocarbons (PAHs) and tobacco-specific nitrosamines (TSNAs). Preliminary data suggest that members of the minimally-studied UGT2A and 3A sub-families of metabolizing enzymes are expressed in tobacco target tissues including lung and H&N, exhibit activity against tobacco carcinogens, and that polymorphic and splicing variants exist that alter their activity, thus potentially altering local detoxification of tobacco carcinogens at these targt sites. These characteristics suggest that UGT2A and 3A enzymes are potentially important susceptibility markers for tobacco-related cancers. The goal of this proposal is to test our hypothesis that UGT2A and 3A activity is important in the local detoxification of tobacco carcinogens in tobacco target tissues, and that UGT2A and 3A activities and expression are altered via genotypic and splicing mechanisms and play a role in risk of tobacco-related cancers.
The specific aims of this proposal are to, (1) Characterize the expression and activity of UGT2A and 3A enzymes; (2) Examine the importance of UGT2A and 3A SNPs to risk for cancers of the lung and H&N; and (3) Examine UGT2A and 3A splicing mechanisms as a form of UGT2A and 3A regulation by determining whether UGT2A and 3A splice variants function to regulate UGT conjugating activities and potentially act to alter tobacco-related cancer risk. The proposed studies will enable us to better understand the potential role of the UGT2A and 3A enzymes as susceptibility markers for tobacco- related cancer induction, help us identify subjects for targeted prevention strategies, and enable us to evaluate the innovative concept that differential splicing may act as a form of gene regulation that plays a role in cancer risk.

Public Health Relevance

Members of the UGT2A and 3A family of phase II metabolizing enzymes are expressed in tobacco target sites including lung and head and neck (H&N), exhibit activity against tested tobacco carcinogens, and have functional polymorphic and splice variants that alter their activity, potentially altering the detoxification of tobacco carcinogens at target sites, suggesting that UGT2A and 3A enzymes have potential as susceptibility markers for tobacco-related cancers. The goal of this proposal is to test our hypothesis that UGT2A and 3A activity is important in the local detoxification of tobacco carcinogens in tobacco target tissues, and that UGT2A and 3A activities and expression are altered via genotypic and splicing mechanisms and play a role in risk of tobacco-related cancers. The proposed studies will enable us to better understand the potential role of the UGT2A and 3A enzymes as susceptibility markers for tobacco-related cancer induction, help us identify subjects for targeted prevention strategies, and enable us to evaluate the innovative concept that differential splicing may be an important mechanism of gene regulation that plays a role in cancer risk.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES025460-02
Application #
9131748
Study Section
Xenobiotic and Nutrient Disposition and Action Study Section (XNDA)
Program Officer
Tyson, Frederick L
Project Start
2015-09-01
Project End
2020-05-31
Budget Start
2016-06-01
Budget End
2017-05-31
Support Year
2
Fiscal Year
2016
Total Cost
Indirect Cost
Name
Washington State University
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
041485301
City
Pullman
State
WA
Country
United States
Zip Code
99164
Ashmore, Joseph H; Luo, Shaman; Watson, Christy J W et al. (2018) Carbonyl Reduction of NNK by Recombinant Human Lung Enzymes. Identification of HSD17?12 as the Reductase important in (R)-NNAL formation in Human Lung. Carcinogenesis :
Perez-Paramo, Yadira X; Chen, Gang; Ashmore, Joseph H et al. (2018) Nicotine-N'-oxidation by flavin monooxygenase enzymes. Cancer Epidemiol Biomarkers Prev :
Denton, Travis T; Srivastava, Pramod; Xia, Zuping et al. (2018) Identification of the 4-Position of 3-Alkynyl and 3-Heteroaromatic Substituted Pyridine Methanamines as a Key Modification Site Eliciting Increased Potency and Enhanced Selectivity for Cytochrome P-450 2A6 Inhibition. J Med Chem 61:7065-7086
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
Remsberg, Connie M; Bray, Brenda S; Wright, Susan K et al. (2017) Design, Implementation, and Assessment Approaches Within a Pharmacogenomics Course. Am J Pharm Educ 81:11
Fehringer, Gordon; Brenner, Darren R; Zhang, Zuo-Feng et al. (2017) Alcohol and lung cancer risk among never smokers: A pooled analysis from the international lung cancer consortium and the SYNERGY study. Int J Cancer 140:1976-1984
Boffetta, Paolo; Hayes, Richard B; Sartori, Samantha et al. (2016) Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium. Eur J Cancer Prev 25:344-8
Chen, Gang; Luo, Shaman; Kozlovich, Shannon et al. (2016) Association between Glucuronidation Genotypes and Urinary NNAL Metabolic Phenotypes in Smokers. Cancer Epidemiol Biomarkers Prev 25:1175-1184
White Jr, John R; Padowski, Jeannie M; Zhong, Yili et al. (2016) Pharmacokinetic analysis and comparison of caffeine administered rapidly or slowly in coffee chilled or hot versus chilled energy drink in healthy young adults. Clin Toxicol (Phila) 54:308-12
Chen, Li-Shiun; Baker, Timothy; Hung, Rayjean J et al. (2016) Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis. EBioMedicine 11:219-226

Showing the most recent 10 out of 18 publications